US20050124549A1 - Method of modulating the proliferation of medullary thyroid carcinoma cells - Google Patents

Method of modulating the proliferation of medullary thyroid carcinoma cells Download PDF

Info

Publication number
US20050124549A1
US20050124549A1 US10/469,835 US46983504A US2005124549A1 US 20050124549 A1 US20050124549 A1 US 20050124549A1 US 46983504 A US46983504 A US 46983504A US 2005124549 A1 US2005124549 A1 US 2005124549A1
Authority
US
United States
Prior art keywords
sstr
agonist
cys
pharmaceutically acceptable
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/469,835
Other languages
English (en)
Inventor
Ettore Uberti
Maria Zatelli
Michael Dewitt Culler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ipsen Pharma SAS
Universita degli Studi di Ferrara
Original Assignee
Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Universita degli Studi di Ferrara
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS, Universita degli Studi di Ferrara filed Critical Societe de Conseils de Recherches et dApplications Scientifiques SCRAS SAS
Priority to US10/469,835 priority Critical patent/US20050124549A1/en
Assigned to UNIVERSITA DEGLI STUDI DI FERRARA reassignment UNIVERSITA DEGLI STUDI DI FERRARA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: UBERTI, ETTORE C. DEGLI, ZATELLI, MARIA C.
Assigned to BIOMEASURE, INCORPORATED reassignment BIOMEASURE, INCORPORATED ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CULLER, MICHAEL DEWITT
Assigned to SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. reassignment SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES, S.A.S. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BIOMEASURE, INCORPORATED
Publication of US20050124549A1 publication Critical patent/US20050124549A1/en
Priority to US11/799,594 priority patent/US9220760B2/en
Priority to US11/810,268 priority patent/US20110183416A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Definitions

  • Somatostatin a tetradecapeptide discovered by Brazeau et al., has been shown to have potent inhibitory effects on various secretory processes in tissues such as pituitary, pancreas and gastrointestinal tract. SS also acts as a neuromodulator in the central nervous system.
  • SSTR1-SSTR5 G protein coupled receptors
  • Somatostatin binds to the five distinct receptor (SSTR) subtypes with relatively high and equal affinity for each subtype.
  • SSTR2 somatostatin type-2 receptor
  • SSTR5 somatostatin type-5 receptor
  • Activation of types 2 and 5 have been associated with growth hormone suppression and more particularly GH secreting adenomas (Acromegaly) and TSH secreting adenomas. Activation of type 2 but not type 5 has been associated with treating prolactin secreting adenomas.
  • somatostatin receptor subtypes include inhibition of insulin and/or glucagon for treating diabetes mellitus, angiopathy, proliferative retinopathy, dawn phenomenon and nephropathy; inhibition of gastric acid secretion and more particularly peptic ulcers, enterocutaneous and pancreaticocutaneous fistula, irritable bowel syndrome, Dumping syndrome, watery diarrhea syndrome, AIDS related diarrhea, chemotherapy-induced diarrhea, acute or chronic pancreatitis and gastrointestinal hormone secreting tumors; treatment of cancer such as hepatoma; inhibition of angiogenesis; treatment of inflammatory disorders such as arthritis; retinopathy; chronic allograft rejection; angioplasty; preventing graft vessel and gastrointestinal bleeding. It is preferred to have an analog which is selective for the specific somatostatin receptor subtype or subtypes responsible for the desired biological response, thus, reducing interaction with other receptor subtypes which could lead to undesirable side effects.
  • MTC medullary thyroid carcinoma
  • the present invention relates to the discovery that the human MTC cell line TT, which displays MTC cell characteristics (Zabel M, et al., 1992 Histochemistry 102: 323-327, 2 Gagel R F, et al., 1986 Endocrinology 118: 1643-1651, Liu J L, et al., 1995 Endocrinology 136: 2389-2396) and which stably expresses all the SSTR subtypes, responds to SSTR2 and SSTR5 activation by subtype selective agonists with two different patterns in terms of [ 3 H]thy incorporation and cell number.
  • SSTR2 preferential agonists significantly suppress [ 3 H]thy incorporation, i.e., inhibit DNA synthesis, and reduce cell proliferation.
  • SSTR5 selective agonists significantly increase [ 3 H]thy incorporation in TT cells, i.e., increase DNA synthesis, but alone fail to influence cell proliferation. Further, SSTR2 antagonists counteract the action of SSTR2 preferential agonists on TT cells. Further still, increasing concentrations of an SSTR5 selective agonist dose-dependently prevents the suppression of TT cell [ 3 H]thy incorporation and proliferation produced by an SSTR2 preferential agonist, and vice versa, showing an antagonism between such agonists.
  • SSTR2 and SSTR5 preferential agonists exert differential effects on proliferation of human medullary thyroid TT cell line in vitro, according to their specific SSTR selectivity. Proliferation of the TT cell line can be reduced by SSTR2 selective agonists, but not by SSTR5 agonists, and an SSTR5 agonist can prevent SSTR2 mediated antiproliferative effects.
  • SSTR2 selective agonists but not by SSTR5 agonists
  • SSTR5 agonist can prevent SSTR2 mediated antiproliferative effects.
  • the key inhibitory role of SSTR2 on MTC cell proliferation demonstrates that analogues with enhanced SSTR2 affinity and selectivity versus SSTR5 would be useful as antiproliferative agents in MTC treatment.
  • the present invention is based on the discovery that somatostatin agonists selective for SSTR-2 are effective in reducing the rate of proliferation of medullary thyroid carcinoma cells, and that somatostatin agonists selective for SSTR-5 are effective in attenuating this SSTR-2 agonist-induced reduction in rate of proliferation.
  • the present invention is directed to a method of modulating the rate of proliferation of MTC cells which comprises contacting MTC cells with one or more SSTR2 agonist and one or more SSTR5 agonist, wherein said SSTR2 agonist serves to reduce the rate of proliferation of the MTC cells and said SSTR5 agonist serves to attenuate the SSTR-2 agonist-induced reduction in proliferation rate.
  • the invention is directed to the immediately foregoing method wherein said SSTR-5 agonist is D-Phe-Phe-Trp-D-Trp-Lys-Thr-Phe-Thr-NH 2 or a pharmaceutically acceptable salt thereof.
  • the invention is directed to a method of decreasing the rate of proliferation of medullary thyroid carcinoma cells which comprises contacting medullary thyroid carcinoma cells with one or more SSTR2 agonist or a pharmaceutically acceptable salt thereof.
  • the SSTR-2 agonist is a SSTR-2 selective agonist.
  • the SSTR-2 agonist or pharmaceutically acceptable salt thereof has a Ki value for SSTR-5 that is at least 2 times higher than it has for SSTR-2, more preferably at least 5 times higher than it has for SSTR-2, more preferably still at least 10 times higher than it has for SSTR-2.
  • the SSTR-2 agonist or pharmaceutically acceptable salt thereof has a Ki value of less than 5 nM, more preferably less than 1 nM.
  • the SSTR-2 selective agonist is a compound selected from the list consisting of D-Nal-cyclo[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH 2 , cyclo [Tic-Tyr-D-Trp-Lys-Abu-Phe], 4-(2-Hydroxyethyl)-1-piperazinylacetyl-D-Phe-cyclo(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH 2 , and 4-(2-Hydroxyethyl)-1-piperazine-2-ethanesulfonyl-D-Phe-cyclo(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH 2 ; or a pharmaceutically acceptable salt thereof, wherein “4-(2-Hydroxyethyl
  • the invention is directed to a method of treating medullary thyroid carcinoma which comprises administering to a patient in need thereof an effective amount of a SSTR2 agonist.
  • the SSTR-2 agonist is a SSTR-2 selective agonist.
  • the SSTR-2 agonist or pharmaceutically acceptable salt thereof has a Ki value for SSTR-5 that is at least 2 times higher than it has for SSTR-2, more preferably at least 5 times higher than it has for SSTR-2, more preferably still at least 10 times higher than it has for SSTR-2.
  • the SSTR-2 agonist or pharmaceutically acceptable salt thereof has a Ki value of less than 5 nM, more preferably less than 1 nM.
  • the SSTR-2 selective agonist is a compound selected from the list consisting of D-Nal-cyclo[Cys-Tyr-D-Trp-Lys-Val-Cys]-Thr-NH 2 , cyclo[Tic-Tyr-D-Trp-Lys-Abu-Phe], 4-(2-Hydroxyethyl)-1-piperazinylacetyl-D-Phe-cyclo(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH 2 , and 4-(2-Hydroxyethyl)-1-piperazine-2-ethanesulfonyl-D-Phe-cyclo(Cys-Tyr-D-Trp-Lys-Abu-Cys)-Thr-NH 2 ; or a pharmaceutically acceptable salt thereof, wherein “4-(2-Hydroxyethyl)
  • the invention provides a method of treating medullary thyroid carcinoma patient comprising administering to a patient in need thereof an effective amount of a SSTR2 agonist or a pharmaceutically acceptable salt thereof, wherein said SSTR-2 agonist or pharmaceutically acceptable salt thereof comprises a Tyr(I) residue, wherein the iodine atom of said Tyr(I) residue comprises a radioactive iodine isotope.
  • said iodine isotope comprises 125 I, 127 I or 131 I.
  • medullary thyroid carcinoma cells have formed metastases outside the thyroid.
  • said metastases are present in the lymph, the lung, the liver, the brain, or in bone.
  • FIG. 1 In vitro SSTR2 mediated intracellular calcium mobilization
  • CHO-K 1 cells expressing the human SSTR2 were harvested as described in Material and Methods and then the SS analogues (10 ⁇ 7 -10 ⁇ 6 M) were added for measurement of intracellular Ca 2+ mobilization, expressed as the ratio between the intracellular calcium concentration measured after the addition of SS analogues and the value observed at basal level.
  • the excitation and emission wavelengths were 340 and 510 nm, respectively. The data are represented as mean ⁇ SEM.
  • FIG. 2 In vitro SSTR5 mediated intracellular calcium mobilization
  • CHO-K1 cells expressing the human SSTR5
  • SS analogues (10 ⁇ 7 -10 ⁇ 6 M) were added for measurement of intracellular Ca 2+ mobilization, expressed as the ratio between the intracellular calcium concentration measured after the addition of SS analogues (Compound 1, Compound 5 and Compound 6) and the value observed at basal level.
  • the excitation and emission wavelengths were 340 and 510 nm, respectively. The data are represented as mean ⁇ SEM.
  • FIG. 3 In vitro inhibition of SS-stimulated intracellular calcium mobilization by SSTR2 antagonist
  • CHO-K1 cells expressing the human SSTR2, were harvested as described in Material and Methods, and then Compound 6 (10 ⁇ 9 -10 ⁇ 6 M) and SS (10 nM) were added for measurement of the effect of Compound 6 on SS (10 ⁇ 8 M)-stimulated intracellular calcium mobilization, and expressed as the percentage vs. SS alone.
  • the excitation and emission wavelengths were 340 and 510 nm, respectively. The data are represented as mean ⁇ SEM.
  • FIG. 4 Somatostatin receptors mRNA expression in TT cells.
  • RNA (1 ⁇ g/reaction) was treated with deoxyribonuclease and subjected to reverse transcription using Oligo(dT) as primer. Samples incubated without RT enzyme served as control. Aliquots from the generated cDNA and the negative controls were subjected to subsequent PCR amplification of SSTR's, using the primers indicated in Table 1. PCR products were resolved on a 2% agarose gel. The expected PCR products of SSTR 1-5 are depicted in A (lane M, PCR Marker; G, PCR product of GAPDH amplification).
  • FIG. 5 Effect of SS analogues on [ 3 H]thy incorporation in TT cells.
  • FIG. 6 Effect of SS analogues on TT cells proliferation.
  • FIG. 7 Effect of SSTR2 selective antagonist on T[cell [ 3 H]thy incorporation and cell proliferation during treatment with SSTR2 agonist.
  • FIG. 8 Effect of SSTR5 selective agonist on TT cell [ 3 H]thy incorporation and cell proliferation during treatment with SSTR2 selective agonist.
  • Lower panel Cells were incubated in 96-well plates for 48 hours in a culture medium supplemented with Compound 2 (10 ⁇ 7 M) without or with increasing concentrations of Compound 5 (10 ⁇ 9 , 10 ⁇ 8 , 10 ⁇ 7 , and 10 ⁇ 6 M), or with Compound 5 (10 ⁇ 7 M) with or without decreasing concentrations of Compound 2 (10 ⁇ 6 , 10 ⁇ 7 , 10 ⁇ 8 , and 10 ⁇ 9 M).
  • Control wells were treated with vehicle solution and TT cell proliferation was measured as absorbance at 490 nM of each well. Data from six individual experiments were evaluated independently with eight replicates expressed as the mean ⁇ SEM percent cell proliferation inhibition versus untreated control cells *P ⁇ 0.05 and **P ⁇ 0.01 vs. control.
  • somatostatin receptors e.g., SSTR-1, SSTR-2, SSTR-3, SSTR-4, and SSTR-5.
  • a somatostatin agonist may be one or more of an SSTR-1 agonist, SSTR-2 agonist, SSTR-3 agonist, SSTR-4 agonist or a SSTR-5 agonist.
  • a somatostatin type-2 receptor agonist i.e., SSTR-2 agonist
  • SSTR-2 agonist is a compound which (1) has a high binding affinity (e.g., Ki of less than 100 nM or preferably less than 10 nm or less than 1 nM) for SSTR-2 (e.g., as defined by the receptor binding assay described below) and (2) decreases the rate of proliferation of medullary thyroid carcinoma cells (e.g., as shown by the biological assay described below).
  • a somatostatin type-2 receptor selective agonist is a somatostatin type-2 receptor agonist which has a higher binding affinity (i.e., lower Ki) for SSTR-2 than for SSTR-5.
  • a somatostatin type-5 receptor agonist is a somatostatin agonist which (I) has a high binding affinity (e.g., Ki of less than 100 nM or preferably less than 10 nm or less than 1 nM) for SSTR-5 (e.g., as defined by the receptor binding assay described below) and (2) attenuates the SSTR-2 agonist-induced decrease in the rate of proliferation of medullary thyroid carcinoma cells (e.g., as shown by the biological assay described below).
  • a somatostatin type-5 receptor selective agonist is a somatostatin type-5 receptor agonist which has a higher binding affinity (i.e., lower Ki) for SSTR-5 than for SSTR-2.
  • the SSTR-2 agonist is also a SSTR-2 selective agonist.
  • the SSTR-2 selective agonist has a Ki value for SSTR-5 that is at least 2 times (e.g., at least 5 times or at least 10 times) higher than it has for the SSTR-2 receptor (e.g., as defined by the receptor binding assay described below).
  • SSTR-2 agonists which may be used to practice the present invention include, but are not limited to:
  • SSTR-5 agonist which may be used to practice the present invention includes, but is not limited to:
  • somatostatin agonists are those covered by formulae or those specifically recited in the publications set forth below, all of which are hereby incorporated by reference.
  • each amino acid residue represents the structure of —NH—C(R)H—CO—, in which R is the side chain (e.g., CH 3 for Ala).
  • Lines between amino acid residues represent peptide bonds which join the amino acids.
  • the amino acid residue is optically active, it is the L-form configuration that is intended unless D-form is expressly designated.
  • disulfide bonds e.g., disulfide bridge
  • Cys residues residues are not shown.
  • Abbreviations of the common amino acids are in accordance with IUPAC-IUB recommendations.
  • Synthesis of short amino acid sequences is well established in the peptide art.
  • synthesis of H-D-Phe-Phe-Phe-D-Trp-Lys-Thr-Phe-Thr-NH 2 can be achieved by following the protocol set forth in Example I of European Patent Application 0 395 417 A1.
  • the synthesis of somatostatin agonists with a substituted N-terminus can be achieved, for example, by following the protocol set forth in WO 88/02756, European Patent Application No. 0 329 295, and PCT Publication No. WO 94/04752.
  • Some of the compounds of the instant invention can have at least one asymmetric center. Additional asymmetric centers may be present on the molecule depending upon the nature of the various substituents on the molecule. Each such asymmetric center will produce two optical isomers and it is intended that all such optical isomers, as separated, pure or partially purified optical isomers, racemic mixtures or diastereomeric mixtures thereof, are included within the scope of the instant invention.
  • the compounds of the instant invention generally can be isolated in the form of their pharmaceutically acceptable acid addition salts, such as the salts derived from using inorganic and organic acids.
  • acids are hydrochloric, nitric, sulfuric, phosphoric, formic, acetic, trifluoroacetic, propionic, maleic, succinic, D-tartaric, L-tartaric, malonic, methane sulfonic and the like.
  • certain compounds containing an acidic function such as a carboxy can be isolated in the form of their inorganic salt in which the counter-ion can be selected from sodium, potassium, lithium, calcium, magnesium and the like, as well as from organic bases.
  • the pharmaceutically acceptable salts can be formed by taking about 1 equivalent of a SSTR-2 agonist, e.g., compound 1, and contacting it with about 1 equivalent or more of the appropriate corresponding acid of the salt which is desired. Work-up and isolation of the resulting salt is well-known to those of ordinary skill in the art.
  • the compounds of this invention can be administered by oral, parenteral (e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant), nasal, vaginal, rectal, sublingual or topical routes of administration and can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.
  • parenteral e.g., intramuscular, intraperitoneal, intravenous or subcutaneous injection, or implant
  • nasal, vaginal, rectal, sublingual or topical routes of administration can be formulated with pharmaceutically acceptable carriers to provide dosage forms appropriate for each route of administration.
  • the present invention includes within its scope pharmaceutical compositions comprising, as an active ingredient, at least one SSTR-2 agonist in association with a pharmaceutically acceptable carrier.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
  • the active compound is admixed with at least one inert pharmaceutically acceptable carrier such as sucrose, lactose, or starch.
  • Such dosage forms can also comprise, as is normal practice, additional substances other than such inert diluents, e.g., lubricating agents such as magnesium stearate.
  • the dosage forms may also comprise buffering agents. Tablets and pills can additionally be prepared with enteric coatings.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, the elixirs containing inert diluents commonly used in the art, such as water. Besides such inert diluents, compositions can also include adjuvants, such as wetting agents, emulsifying and suspending agents, and sweetening, flavoring and perfuming agents.
  • Preparations according to this invention for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, or emulsions.
  • non-aqueous solvents or vehicles are propylene glycol, polyethylene glycol, vegetable oils, such as olive oil and corn oil, gelatin, and injectable organic esters such as ethyl oleate.
  • Such dosage forms may also contain adjuvants such as preserving, wetting, emulsifying, and dispersing agents. They may be sterilized by, for example, filtration through a bacteria-retaining filter, by incorporating sterilizing agents into the compositions, by irradiating the compositions, or by heating the compositions. They can also be manufactured in the form of sterile solid compositions which can be dissolved in sterile water, or some other sterile injectable medium immediately before use.
  • compositions for rectal or vaginal administration are preferably suppositories which may contain, in addition to the active substance, excipients such as coca butter or a suppository wax.
  • compositions for nasal or sublingual administration are also prepared with standard excipients well known in the art.
  • an effective dosage of active ingredient in the compositions of this invention may be varied; however, it is necessary that the amount of the active ingredient be such that a suitable dosage form is obtained.
  • the selected dosage depends upon the desired therapeutic effect, on the route of administration, and on the duration of the treatment, all of which are within the realm of knowledge of one of ordinary skill in the art.
  • dosage levels of between 0.0001 to 100 mg/kg of body weight daily are administered to humans and other animals, e.g., mammals.
  • a preferred dosage range is 0.01 to 10.0 mg/kg of body weight daily, which can be administered as a single dose or divided into multiple doses.
  • RT-PCR analysis was used to demonstrate that all five SSTR subtype mRNA's are expressed in a human MTC cell line, TT.
  • the ability of SS analogues with differing affinity and specificity for SSTR2 and 5 subtypes to influence TT cell proliferative activity may be assessed by considering [ 3 H]thy incorporation, considered an indirect measure of DNA synthetic activity, and number of viable cells.
  • All SSTR2 preferential agonists were able to significantly suppress TT cell number at concentrations ranging from 10 ⁇ 9 M to 10 ⁇ 6 M.
  • Compound 3 and Compound 4 significantly (p ⁇ 0.05) reduced [ 3 H]thy incorporation at 10 ⁇ 9 M but not at 10 ⁇ 8 M and 10 ⁇ 7 M, when their maximal inhibitory effect on cell number was apparent.
  • Each SSTR2 compound tested showed a trend for decreased efficacy with increasing concentration, however, bell-shaped response curves are common for SS.
  • the inhibition of [ 3 H]thy incorporation and TT cell number by Compound 1 and Compound 2 at 10 ⁇ 7 M was not associated with any cytotoxic action, as demonstrated by Trypan Blue staining.
  • the TT cell line was obtained from the American Type Culture Collection (ATCC, Manassas, Va., USA).
  • the TT cell line consists of aneuploid transformed CT-producing parafollicular cells which are characterised by the presence of a TGC to TGG mutation (Cys to Trp) at exon 11 codon 634 in the RET protooncogene (Cooley L D, et al., 1995 Cancer Genet Cytogenet 80: 138-149), a characteristic that we confirmed in the cell line we worked with.
  • TT cells display an impaired expression of the tumor suppressor gene p53 (Velasco J A, et al., 1997 Int J Cancer 73: 449-455).
  • TT cells express CT and CT receptor (Frendo J L, et al., 1994 FEBS Lett. 342: 214-216), carcino-embrionic antigen (CEA), SS, neurotensin, gastrin-releasing peptide (GRP), Leu- and Met-enkephalin, parathyroid hormone releasing peptide (PTHrp), Chromogranin A, SP-I, Synaptophysin, Neuron-specific enolase (NSE), 1,25-dihydroxyvitamin D 3 receptor, Thyrosin hydroxylase, ⁇ -Tubulin, and Cytocheratin (Zabel M, et al., 1995 Histochemical J. 27: 859-868).
  • TT cells secrete a significant amount of CT and respond to changes in ionised calcium levels (Zabel M, et al., 1992 Histochemistry 102: 323-327).
  • the TT cell line is suitable for studies on parafollicular function and responses to endocrine and pharmacological stimuli.
  • the TRIZOL protocol is a modification of the guanidinium/phenyl extraction. Briefly, the cultured cell media was aspirated and the cells washed with 1 ⁇ PBS. The TRIZOL reagent was added and cells lysed at room temperature for 10 min. Chloroform was added to the TRIZOL/cell lysate mixture, and left to stand for 2-3 min, and then centrifuged 12000 ⁇ g for 15 min. The aqueous layer was removed from the centrifuged mixture. Isopropanol was added to precipitate the RNA, the pellet collected, washed with 75% ethanol and dried in air.
  • RNA was resuspended in diethylpyrocarbonate-treated (DEPC) water and quantified using UV spectrophotometry at 260 nM. To prevent DNA contamination, RNA was treated with ribonuclease-free deoxyribonuclease (Promega, Milano, Italy).
  • RT mix in PCR tubes was covered with 50 ⁇ l light white mineral oil (Sigma-Aldrich Corp. Milano, Italy); the RT was carried out in the Minicycler (MJ Research Inc., Watertown, Mass., USA) using a program with the following parameters: 10 min at 70° C., 1 min at 4° C., 5 min at 4° C. After supplementing with SuperScript II, the reaction was completed at 42° C. for 50 min then at 70° for 15 min. Samples were digested with RNAse H (Promega, Milano, Italy) at 37° C. for 20 min, and then stored at ⁇ 20° C. until the first PCR.
  • RNAse H Promega, Milano, Italy
  • the cDNA (I ⁇ l of RT reaction) was then amplified by PCR with 1 U Taq DNA polymerase (Life Technologies, Milano, Italy), in the conditions recommended by suppliers in a 50- ⁇ l reaction mixture. After initial denaturation at 95° C. for 5 min, PCR reactions were carried out using the oligonucleotide primers and the conditions listed in Table 1, describing the size of expected fragments. PCR products were analyzed on a 2% agarose gel and visualized by ethidium bromide (ETB) staining. To assure that no contamination occurred during the course of the RT-PCR procedure, two kinds of negative control were prepared. The first negative control was made by omitting the total RNA in the RT.
  • ETB ethidium bromide
  • the second was prepared by replacing the cDNA mix with water in the PCR reaction.
  • the PCR was considered useful only if no band was observed in the negative control lanes on a 2% agarose gel.
  • Each PCR product was subjected to restriction enzyme digestion and analysed on 2% agarose gel to further confirm the correct identification of the amplicons.
  • SS analogues used in this study and their respective affinities to the different SSTR's are listed in Table 2.
  • BSA bovine serum albumin
  • Specificity and selectivity of the analogues were determined by Radioligand Binding Assay on CHO-K1 cells stably transfected with each of the SSTR subtypes, as follows.
  • the complete coding sequences of genomic fragments of the SSTR 1, 2, 3, and 4 genes and a cDNA clone for SSTR 5 were subcloned into the mammalian expression vector pCMV (Life Technologies, Milano, Italy).
  • Clonal cell lines stably expressing SSTR's 1-5 were obtained by transfection into CHO-K1 cells (ATCC, Manassas, Va., USA) using the calcium phosphate co-precipitation method (Davis L, et al., 1994 In: Basic methods in Molecular Biology, 2nd edition, Appleton & Lange, Norwalk, Conn., USA: 611-646).
  • the plasmid pRSV-neo (ATCC) was included as a selectable marker.
  • Clonal cell lines were selected in RPMI 1640 media containing 0.5 mg/ml of G418 (Life Technologies, Milano, Italy), ring cloned, and expanded into culture.
  • Membranes for in vitro receptor binding assays were obtained by homogenizing the CHO-K1 cells expressing the SSTR's subtypes in ice-cold 50 mM Tris-HCl and centrifuging twice at 39000 g (10 min), with an intermediate resuspension in fresh buffer. The final pellets were resuspended in 10 mM Tris-HCl for assay. For the SSTR 1, 3, 4, and 5 assays, aliquots of the membrane preparations were incubated 90 min. at 25° C.
  • the final assay volume was 0.3 ml.
  • 0.05 nM [ 125 I]MK-678 was employed as the radioligand and the incubation time was 90 min at 25° C.
  • Biological activity of SSTR selective agonists and antagonists was evaluated by the calcium mobilization assay in CHO-K1 cells expressing the human SSTR2 or SSTR5.
  • the cells were harvested by incubating in a 0.3% EDTA/phosphate buffered saline solution (25° C.), and washed twice by centrifugation. The washed cells were resuspended in Hank's-buffered saline solution (HBSS) for loading of the fluorescent Ca 2+ indicator Fura-2AM.
  • HBSS Hank's-buffered saline solution
  • Unloaded Fura-2AM was removed by centrifugation twice in HBBS, and the final suspensions were transferred to a spectrofluorometer (Hitachi F-2000) equipped with a magnetic stirring mechanism and a temperature-regulated cuvette holder. After equilibration to 37° C., the SS analogues were added for measurement of intracellular Ca 2+ mobilization. The excitation and emission wavelengths were 340 and 510 nm, respectively.
  • Compound 2 and Compound 1 stimulated significant intracellular Ca 2+ mobilization (indicated as the ratio between stimulated and basal value), whereas Compound 6 did not, at the concentrations tested.
  • Compound 4 and Compound 3 were also highly potent in stimulating Ca mobilization.
  • Compound 5 and Compound 1 stimulated significant intracellular Ca 2+ mobilization, whereas Compound 6 displayed slight agonist activity in the range of 300 to 1000 nM.
  • Compound 6 inhibited SS-induced intracellular Ca 2+ mobilization in SSTR2 expressing cells in a dose dependent manner with complete suppression of SS action at about 10 ⁇ 7 M. Therefore the evaluation of intracellular Ca 2+ mobilization demonstrated that the biological activity of each of the various analogues was in keeping with its receptor binding profile.
  • TT cells were plated in 24-multiwell plates (10 5 cells/well) and incubated for 48 hours in a medium supplemented with 10% FBS in the presence of [ 3 H]thy (1.5 ⁇ Ci/mL; 87 Ci/mmol) with or without each SS analogue at concentrations ranging from 10 ⁇ 6 to 10 ⁇ 9 M. Treatments were renewed by adding fresh analogues to the wells after the first 24 h of incubation, without removing the medium.
  • TCA-precipitated material was solubilized in 500 ⁇ L 0.2 mol/L sodium hydroxide and 0.1% SDS. Cell-associated radioactivity was then counted in a scintillation spectrometer. Results (counts per min per well) were obtained by determining the mean value of at least six experiments in quadruplicate. The viability of TT cells in control and treated cultures was evaluated by Trypan blue staining both after 24 and 48 hours, and the number of viable cells was always 85-95%.
  • the effects of SSTR selective agonists and antagonists on TT cell proliferation were assessed by the CELLTITER 96 Aqueous Non-Radioactive Cell Proliferation Assay (Promega, Milano, Italy), a colorimetric method for determining the number of viable cells in proliferation assays.
  • the assay contains solutions of a tetrazolium compound (Owen's reagent; MTS) and an electron coupling reagent (phenazine methosulphate; PMS).
  • MTS tetrazolium compound
  • PMS phenazine methosulphate
  • the absorbance of the formazan at 490 nm can be measured directly from 96 well assay plates (Zatelli M C, et al., 2000 J Clin Endocrinol Metab 85: 847-852; Cory A H, et al., 1991 Cancer Coniniun 3: 207-212).
  • the conversion of MTS into the aqueous soluble formazan is accomplished by dehydrogenase enzymes found in metabolically active cells.
  • the quantity of formazan product as measured by the amount of 490 nm absorbance is directly proportional to the number of living cells in culture.
  • TT cells were plated in 96-multiwell plates (2 ⁇ 10 4 cells/well) and incubated for 48 hours in a medium supplemented with 10% FBS in the presence or absence of each SS analogue at concentrations ranging from 10 ⁇ 6 to 10 ⁇ 9 M. Treatments were renewed by adding fresh analogues to the wells after the first 24 hours of incubation. At the end of the incubation period, 20 ⁇ l of a combined MTS/PMS solution were added to each well with a repeating pipette, and the plates were incubated for an additional 4 hours at 37° C. in a humidified 5% CO 2 atmosphere.
  • TT cells express SSTR's that could mediate a potential response to selective compounds for individual SSTR subtypes.
  • RNA was isolated from cultured TT cells and performed RT-PCR reactions in the conditions described in Material and Methods. Integrity of cDNA was assured by the presence of the GAPDH signal. The absence of genomic DNA contamination in the cDNA samples was assessed by the lack of any amplification in a PCR reaction using non-reverse transcribed samples. Positive amplification of SSTR1, 2, 3, 4, and 5 was found in the examined cell line ( FIG. 4 ), demonstrating that these receptors are expressed in human MTC cell-line TT. The demonstration that the TT cell line stably expresses SSTR subtypes made this cellular model system suitable for evaluating the action of receptor-selective SS analogues.
  • [ 3 H]Thy incorporation values obtained with 10 ⁇ 9 to 10 ⁇ 6 M concentrations of SSTR2 preferential agonists (Compound 1, Compound 2, Compound 3, and Compound 4), SSTR5 preferential agonist (Compound 5) and SSTR2 preferential antagonist (Compound 6) are presented in FIG. 5 .
  • Compound 2 significantly suppressed [ 3 H]thy incorporation by 58-23% at concentrations ranging from 10 ⁇ 9 to 10 ⁇ 7 M.
  • Compound 1 significantly suppressed [ 3 H]thy incorporation by 41-21% at concentrations ranging from 10 ⁇ 9 to 10 ⁇ 6 M.
  • SSTR2 preferential agonists an SSTR5 preferential agonist and an SSTR2 preferential antagonist on viable TT cell number at concentrations ranging from 10 ⁇ 9 to 10 ⁇ 6 M are represented in FIG. 6 .
  • all SSTR2 preferential compounds significantly inhibited cell proliferation when compared with untreated control cells at each concentration tested.
  • the selective SSTR5 agonist, Compound 5 produced a slight increase of TT cell proliferation-(up to 11% at 10 ⁇ 8 M), however this did not represent a statistical difference from the untreated control cells.
  • the selective SSTR2 antagonist, Compound 6, did not appear to affect TT cell growth at the concentrations tested.
  • TT cell [ 3 H]thy incorporation and proliferation were examined testing each of Compound 2 and Compound 5 at 10 ⁇ 7 M in combination with increasing doses (from 10 ⁇ 9 M to 10 ⁇ 6 M) of the other compound.
  • the results are summarized in FIG. 8 .
  • Increasing concentrations of the SSTR5 agonist (10 ⁇ 9 M to 10 6 M) dose-dependently prevented the suppression of TT cell [3H]thy incorporation ( FIG. 8 , upper panel) and proliferation ( FIG. 8 , lower panel) produced by the SSTR2 agonist (10 ⁇ 7 M).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US10/469,835 2001-03-06 2002-03-06 Method of modulating the proliferation of medullary thyroid carcinoma cells Abandoned US20050124549A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US10/469,835 US20050124549A1 (en) 2001-03-06 2002-03-06 Method of modulating the proliferation of medullary thyroid carcinoma cells
US11/799,594 US9220760B2 (en) 2001-03-06 2007-05-02 Method of modulating the proliferation of medullary thyroid carcinoma cells
US11/810,268 US20110183416A1 (en) 2001-03-06 2007-06-05 Method of modulating the proliferation of medullary thyroid carcinoma cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27369901P 2001-03-06 2001-03-06
US10/469,835 US20050124549A1 (en) 2001-03-06 2002-03-06 Method of modulating the proliferation of medullary thyroid carcinoma cells
PCT/US2002/006729 WO2002070555A2 (en) 2001-03-06 2002-03-06 Method of modulating the proliferation of medullary thyroid carcinoma cells

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/799,594 Continuation US9220760B2 (en) 2001-03-06 2007-05-02 Method of modulating the proliferation of medullary thyroid carcinoma cells
US11/810,268 Continuation US20110183416A1 (en) 2001-03-06 2007-06-05 Method of modulating the proliferation of medullary thyroid carcinoma cells

Publications (1)

Publication Number Publication Date
US20050124549A1 true US20050124549A1 (en) 2005-06-09

Family

ID=23045039

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/469,835 Abandoned US20050124549A1 (en) 2001-03-06 2002-03-06 Method of modulating the proliferation of medullary thyroid carcinoma cells
US11/799,594 Expired - Fee Related US9220760B2 (en) 2001-03-06 2007-05-02 Method of modulating the proliferation of medullary thyroid carcinoma cells
US11/810,268 Abandoned US20110183416A1 (en) 2001-03-06 2007-06-05 Method of modulating the proliferation of medullary thyroid carcinoma cells

Family Applications After (2)

Application Number Title Priority Date Filing Date
US11/799,594 Expired - Fee Related US9220760B2 (en) 2001-03-06 2007-05-02 Method of modulating the proliferation of medullary thyroid carcinoma cells
US11/810,268 Abandoned US20110183416A1 (en) 2001-03-06 2007-06-05 Method of modulating the proliferation of medullary thyroid carcinoma cells

Country Status (10)

Country Link
US (3) US20050124549A1 (de)
EP (3) EP1390406B1 (de)
JP (2) JP4294959B2 (de)
AT (3) ATE430162T1 (de)
CA (2) CA2743731C (de)
DE (3) DE60236225D1 (de)
ES (3) ES2345280T3 (de)
NO (1) NO20033881L (de)
RU (3) RU2352578C2 (de)
WO (1) WO2002070555A2 (de)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007096055A1 (en) * 2006-02-09 2007-08-30 Novartis, Ag Combination of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes
US20090099094A1 (en) * 2006-03-23 2009-04-16 Marja Chiara Zatelli Use of Somatostatin Agonists to Treat Medullary Thyroid Carcinoma

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262229B1 (en) * 1996-12-04 2001-07-17 Biomeasure Incorporated Somatostatin antagonists
CA2743731C (en) * 2001-03-06 2014-05-06 The Administrators Of The Tulane Educational Fund Method of modulating the proliferation of medullary thyroid carcinoma cells
EP1372688B1 (de) * 2001-03-08 2008-05-07 The Administrators of The Tulane Educational Fund Somatostatin-antagonisten
EP1522311A1 (de) * 2003-10-10 2005-04-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Verwendung von Somatostatin oder seine Derivate zur Herstellung eines Medikamentes zur Regulierung der Ovarialfollikelnreserve bei der nicht menopausierte Frau
EP2835136A1 (de) 2013-08-07 2015-02-11 PregLem S.A. Somatostatin Receptor Modulator zur Unfruchtbarkeitsbehandlung

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597894A (en) * 1995-06-05 1997-01-28 The Louisiana State University Medical Center Foundation Multi-tyrosinated somatostatin analogs
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation
US5972893A (en) * 1997-05-06 1999-10-26 Cedars-Sinai Medical Center Method of treating hyperprolactinemia and prolactinomas
US6180082B1 (en) * 1997-11-24 2001-01-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method to enhance tissue accumulation of radiolabeled compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4661472A (en) * 1985-05-09 1987-04-28 The Salk Institute For Biological Studies GnRH antagonists IX
PT1288223E (pt) 1993-08-09 2005-03-31 Sod Conseils Rech Applic Derivados de peptidos terapeuticos
DE69812084T2 (de) 1997-05-01 2003-12-24 Cedars Sinai Medical Center Verfahren zur behandlung von hyperprolaktinämia und prolaktinomen
CN1250361A (zh) 1997-11-24 2000-04-12 路易斯安那州州立大学及农业机械学院管理委员会 提高放射性标记化合物的组织积累的方法
PL346361A1 (en) 1998-07-30 2002-02-11 Sod Conseils Rech Applic Methods of using a somatostatin analogue
HUP0201696A3 (en) * 1999-06-25 2002-10-28 Sod Conseils Rech Applic Cyclic peptides, pharmaceutical compositions comprising thereof and their use
CA2743731C (en) * 2001-03-06 2014-05-06 The Administrators Of The Tulane Educational Fund Method of modulating the proliferation of medullary thyroid carcinoma cells

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5597894A (en) * 1995-06-05 1997-01-28 The Louisiana State University Medical Center Foundation Multi-tyrosinated somatostatin analogs
US5972893A (en) * 1997-05-06 1999-10-26 Cedars-Sinai Medical Center Method of treating hyperprolactinemia and prolactinomas
US6180082B1 (en) * 1997-11-24 2001-01-30 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method to enhance tissue accumulation of radiolabeled compounds
US5968903A (en) * 1998-05-07 1999-10-19 Biomeasure, Incorporated Inhibition of H. pylori proliferation

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007096055A1 (en) * 2006-02-09 2007-08-30 Novartis, Ag Combination of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes
AU2007218297B2 (en) * 2006-02-09 2010-09-09 Novartis, Ag Combination of Somatostatin-analogs with different selectivity for human Somatostatin receptor subtypes
US8450272B2 (en) 2006-02-09 2013-05-28 Novartis Ag Combinations of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes
US9149510B2 (en) 2006-02-09 2015-10-06 Novartis Ag Combinations of somatostatin-analogs with different selectivity for human somatostatin receptor subtypes
US20090099094A1 (en) * 2006-03-23 2009-04-16 Marja Chiara Zatelli Use of Somatostatin Agonists to Treat Medullary Thyroid Carcinoma

Also Published As

Publication number Publication date
US20110183416A1 (en) 2011-07-28
RU2317824C2 (ru) 2008-02-27
JP2007145854A (ja) 2007-06-14
JP4294959B2 (ja) 2009-07-15
EP1897889A2 (de) 2008-03-12
NO20033881L (no) 2003-10-10
US9220760B2 (en) 2015-12-29
WO2002070555A3 (en) 2003-12-04
ATE466029T1 (de) 2010-05-15
EP1390406A2 (de) 2004-02-25
US20070259811A1 (en) 2007-11-08
ES2328077T3 (es) 2009-11-06
DE60236225D1 (de) 2010-06-10
DE60220157T2 (de) 2008-01-17
ES2345280T3 (es) 2010-09-20
ES2284859T3 (es) 2007-11-16
EP1897889B1 (de) 2010-04-28
EP1897889A3 (de) 2008-03-26
CA2743731C (en) 2014-05-06
EP1813625A1 (de) 2007-08-01
JP2005506289A (ja) 2005-03-03
CA2440214C (en) 2012-05-22
JP4828438B2 (ja) 2011-11-30
EP1390406B1 (de) 2007-05-16
ATE362489T1 (de) 2007-06-15
CA2743731A1 (en) 2002-09-12
EP1813625B1 (de) 2009-04-29
RU2275934C2 (ru) 2006-05-10
RU2003129515A (ru) 2005-03-27
ATE430162T1 (de) 2009-05-15
RU2005132456A (ru) 2007-04-27
DE60232203D1 (de) 2009-06-10
CA2440214A1 (en) 2002-09-12
WO2002070555A2 (en) 2002-09-12
NO20033881D0 (no) 2003-09-02
RU2007111864A (ru) 2008-10-10
DE60220157D1 (de) 2007-06-28
RU2352578C2 (ru) 2009-04-20

Similar Documents

Publication Publication Date Title
US9220760B2 (en) Method of modulating the proliferation of medullary thyroid carcinoma cells
Harel et al. Synergistic interaction between insulin-like growth factors-I and-II in central regulation of pulsatile growth hormone secretion
US20110003749A2 (en) Use of somatostatin or one of its analogues for preparing a medicament intended to regulate the ovarian follicular reserve in non-menopausal women
EP1553969A1 (de) Verwendung von ghrelin zur behandlung von unterernährung von gastrektomiepatienten
US20040198653A1 (en) Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof
EP1541171B1 (de) Mittel zum senken des blutglukosespiegels
US5972893A (en) Method of treating hyperprolactinemia and prolactinomas
Cap et al. Somatostatin Analogues in vitro
EP2003967B1 (de) Verwendung von somatostatin-agonisten zur behandlung von medullärem schilddrüsenkarzinom
Petrides et al. Lactic Acid Does Not Directly Activate Hypothalamic‐Pituitary Corticotroph Function
AU2002316361A1 (en) Pharmaceutical compositions which inhibit proliferation of pituitary adenomas and method of use thereof
Huang Regulation of steriodogenesis in rodent leydig cells by corticotropin-releasing hormone (CRH)
EP1332762A1 (de) Methode zur Behandlung von Hyperprolaktinämia und Prolaktinomen

Legal Events

Date Code Title Description
AS Assignment

Owner name: UNIVERSITA DEGLI STUDI DI FERRARA, ITALY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:UBERTI, ETTORE C. DEGLI;ZATELLI, MARIA C.;REEL/FRAME:015326/0108

Effective date: 20041027

AS Assignment

Owner name: BIOMEASURE, INCORPORATED, MASSACHUSETTS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:CULLER, MICHAEL DEWITT;REEL/FRAME:015343/0982

Effective date: 20041103

AS Assignment

Owner name: SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:BIOMEASURE, INCORPORATED;REEL/FRAME:015356/0527

Effective date: 20041105

STCB Information on status: application discontinuation

Free format text: ABANDONED -- AFTER EXAMINER'S ANSWER OR BOARD OF APPEALS DECISION